{"id":"NCT01715805","sponsor":"Forest Laboratories","briefTitle":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-15","primaryCompletion":"2016-06-24","completion":"2016-06-24","firstPosted":"2012-10-29","resultsPosted":"2019-08-28","lastUpdate":"2019-08-28"},"enrollment":1022,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Antidepressant Therapy (ADT)","otherNames":[]}],"arms":[{"label":"Placebo + ADT Lead-in","type":"OTHER"},{"label":"Placebo + ADT (Double-Blind)","type":"PLACEBO_COMPARATOR"},{"label":"Cariprazine + ADT (Double-Blind)","type":"EXPERIMENTAL"},{"label":"Placebo + ADT (Continued Treatment)","type":"OTHER"}],"summary":"The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD","primaryOutcome":{"measure":"Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period","timeFrame":"Baseline (Week 8)","effectByArm":[{"arm":"Placebo + ADT (Double-Blind)","deltaMin":25.2,"sd":6.1},{"arm":"Cariprazine + ADT (Double-Blind)","deltaMin":25.4,"sd":5.5}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":85,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["30618475"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":1022},"commonTop":["Headache","Nausea","Insomnia","Diarrhoea","Akathisia"]}}